Effective April 1, 2024: Pharmacy and Biopharmacy Policies
Date: 03/21/24
Superior HealthPlan has added and updated certain pharmacy and biopharmacy policies to ensure medical necessity review criteria is current and appropriate for members and the scope of services provided. As a result, the following policies are effective on April 1, 2024, at 12:00AM.
Changes in these policies reflect preauthorization requirement amendments that are less burdensome to insureds, physicians, or health care providers.
POLICY | APPLICABLE PRODUCTS | NEW POLICY OVERVIEW OR UPDATED POLICY REVISIONS |
Dasatinib (Sprycel, Phyrago) (CP.PHAR.72) | Ambetter | Policy updates include:
|
To review all policies, please visit Superior’s Clinical, Payment & Pharmacy Policies webpage.
Prior to updates, pharmacy and biopharmacy clinical policies are reviewed and approved by the Pharmacy and Therapeutics (P&T) Committee.
For questions or additional information, please contact Superior’s Pharmacy Department at 1-800-218-7453, ext. 22272.